Immunome (NASDAQ:IMNM) Stock Price Down 7% – What’s Next?

05 Jan 2026, 14:58 by Teresa Graham · The Cerbat Gem

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares traded down 7% on Monday . The stock traded as low as $19.71 and last traded at $19.3670. 230,996 shares were traded during mid-day trading, a decline of 79% from the average session volume of 1,076,331 shares. The stock had previously closed at $20.82.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IMNM shares. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Truist Financial started coverage on Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price target on the stock. Evercore ISI upped their price objective on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Finally, Guggenheim boosted their target price on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $30.09.

Get Our Latest Stock Analysis on Immunome

Immunome Stock Down 5.1%

The stock has a market cap of $1.81 billion, a PE ratio of -6.68 and a beta of 2.22. The company’s fifty day moving average is $18.86 and its 200 day moving average is $13.60.

Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall bought 4,729 shares of the stock in a transaction dated Tuesday, December 30th. The stock was acquired at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the purchase, the chief executive officer owned 665,254 shares in the company, valued at $14,070,122.10. This represents a 0.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philip Tsai bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the completion of the acquisition, the insider owned 43,300 shares in the company, valued at approximately $887,217. This trade represents a 30.03% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 68,518 shares of company stock valued at $1,453,958 over the last quarter. Company insiders own 7.69% of the company’s stock.

Institutional Investors Weigh In On Immunome

Large investors have recently added to or reduced their stakes in the company. Assetmark Inc. acquired a new position in Immunome in the 3rd quarter worth $39,000. BNP Paribas Financial Markets lifted its stake in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the last quarter. BIT Capital GmbH acquired a new stake in Immunome during the 3rd quarter valued at approximately $69,000. Finally, Russell Investments Group Ltd. purchased a new stake in Immunome during the 3rd quarter worth approximately $76,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.